Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic ...
Hosted on MSN
How Proteins Are Made: From DNA to Function
Proteins are essential biological molecules that perform a vast array of functions crucial for life, from catalyzing biochemical reactions and transporting molecules to providing structural support ...
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA ...
The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.
Analysis of more than 1 million people shows that mental-health disorders fall into five clusters, each of them linked to a ...
Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular snapshots of human polynucleotide phosphorylase (hPNPase) in action, ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback